Andere Sprachen DiaMedica Therapeutics Inc.

Aktien

A2N9HB

CA25253X2077

DMAC

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:19:48 28.06.2024			% 5 Tage	% 1. Jan.
2.94 ^USD	-3.61%		+36.11%	+3.52%

27.06.	Transcript : DiaMedica Therapeutics Inc. - Special Call
26.06.	DiaMedica Therapeutics Inc. plant die Ausweitung seiner klinischen Studien auf Präeklampsie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

DiaMedica Therapeutics Announces Expansion of DM199 Program into Preeclampsia	27.06.
DiaMedica Therapeutics Announces $11.8 Million Private Placement	26.06.
DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia	26.06.
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia	26.06.
DiaMedica Therapeutics Inc. announced that it expects to receive $11.8 million in funding	25.06.
DiaMedica Therapeutics Inc. Elects Rick Pauls as Director	23.05.
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results	08.05.
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024	02.05.
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	17.04.
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	17.04.
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	17.04.
DiaMedica Therapeutics Inc. Announces Executive Changes	10.04.
DiaMedica Therapeutics Files $100 Million Mixed Shelf	21.03.
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results	19.03.
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference	29.01.
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	22.01.
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22.01.
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen DiaMedica Therapeutics Inc.

Aktien

A2N9HB

CA25253X2077

DMAC

Andere Sprachen

Filter